Skip to main content

Table 1 Phenotype of neoplastic stem cells (NSC) in hematologic neoplasms

From: Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Neoplasm

Defined cell subsets containing NSC

Cell surface antigens aberrantly expressed or overexpressed on neoplastic SC

AML

CD34+/CD38− [32]

CD25 [75], CD33 [76], CD52[77]

CD96 [68], CD123 [69]

  
  

CLL-1 [67]

AML

CD34+/CD38+ [38]

n.k.

AMLNPM1mutated

CD34− blast-like [78]

n.k.

MDS

CD34+ [79]

CD123 [80]

MDS with 5q-

CD34+/CD38− [81]

CD52 [77], CD123

MPN

CD34+ [82]

n.k.

CML CD123 [86], IL-1RAP [87]

CD34+/CD38− [17]

CD25 [83], CD26 [84], CD33 [85]

Ph + ALL

CD34+/CD38−/CD19+ [88]

CD25, CD26a, CD52

Ph − ALL

CD34+/CD19+ [89]

n.k.

CLL

CD34+/CD19+ [90]

CD5

Myeloma

CD20+/CD27+/CD138− [91]

n.k.

  1. AML, acute myeloid leukemia; MDS, myelodysplastic syndrome(s); MPN, myeloproliferative neoplasm(s); CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL; chronic lymphocytic leukemia; n.k., not known; NSC, neoplastic stem cells; SC, stem cell; Ph+, Philadelphia chromosome-positive; Ph−, Philadelphia chromosome-negative; IL-1RAP, interleukin-1 receptor accessory protein. aIn a subset of patients with Ph + ALL, LSC express CD26.